IDEAYA Partners with Roche to Test Pancreatic Cancer Drug Combo
Event summary
- IDEAYA Biosciences and Roche will collaborate on a clinical trial combining IDE892 (PRMT5 inhibitor) with RG6505 (pan-RAS inhibitor) for MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma (PDAC).
- IDEAYA will sponsor the trial, with Roche supplying RG6505; both retain commercial rights to their respective compounds.
- MTAP deletion occurs in up to 40% of PDAC cases, with nearly all harboring co-occurring RAS mutations.
- The collaboration may expand to evaluate a triplet combination with IDE397 (MAT2A inhibitor) upon joint approval.
The big picture
This collaboration aligns with IDEAYA's strategy to develop targeted therapies for genetically defined cancers, addressing a high unmet need in PDAC. The partnership with Roche leverages complementary assets—IDEAYA's PRMT5 inhibitor and Roche's pan-RAS inhibitor—to explore combination therapies that could redefine treatment for a significant subset of pancreatic cancer patients. The success of this trial could validate IDEAYA's approach to synthetic lethality in oncology.
What we're watching
- Clinical Efficacy
- Whether the IDE892 and RG6505 combination demonstrates superior efficacy in MTAP-deleted PDAC patients compared to existing treatments.
- Regulatory Pathway
- The pace at which the trial progresses and whether it meets endpoints to support future regulatory approvals.
- Commercial Strategy
- How IDEAYA and Roche navigate commercial rights while potentially expanding the collaboration to include a triplet therapy.
Related topics